Eupraxia Reports Durable 52-Week Symptom Relief With EP-104GI in Eosinophilic Esophagitis Trial

Eupraxia Pharmaceuticals Inc. has announced additional 52-week follow-up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration of EP-104GI for the treatment of eosinophilic esophagitis (EoE). The data show that in Cohort 6, all three patients maintained clinical benefit at 52 weeks, with two out of three remaining in clinical remission. These results are consistent with previously reported long-term data from Cohort 5. At week 24, across Cohorts 4-8, 79% of patients were in clinical remission, with an average SDI score reduction of 69%. No serious adverse events or cases of oral or gastrointestinal candidiasis have been reported over more than 200 patient-months of follow-up. The previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007294), on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here